Building Capacity to Increase Commercial Tobacco Cessation
ID: 349886Type: Posted
Overview

Buyer

Centers for Disease Control - NCCDPHP (HHS-CDC-NCCDPHP)

Award Range

$225K - $9M

Eligible Applicants

Unrestricted

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349886
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Feb 21, 2024 12:00 AM
  4. 4
    Due Apr 24, 2024 12:00 AM
Description

The Centers for Disease Control - NCCDPHP is offering a funding opportunity titled "Building Capacity to Increase Commercial Tobacco Cessation". This opportunity aims to build the capacity of state and territorial tobacco control programs and their partners to translate the science of tobacco cessation into public health interventions. The goal is to increase the number of people who make an attempt to quit using tobacco products and who succeed in quitting. The funding will prioritize interventions that reach population groups disproportionately impacted by tobacco use and cessation-related disparities. The funding opportunity has a projected 60-month (5-year) period of performance with three awards, each projected to have a 12-month budget of $300,000. The deadline for electronically submitted applications is 11:59 pm ET on April 24, 2024. For more information, contact Anna Schecter at zho7@cdc.gov.

Point(s) of Contact
zho7@cdc.gov
Files
No associated files provided.
Similar Opportunities
Tobacco Regulatory Science (R01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Tobacco Regulatory Science (R01 Clinical Trial Optional)". This grant aims to support biomedical and behavioral research that will provide scientific data to inform the regulation of tobacco products in order to protect public health. The research projects funded by this grant must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The grant does not require cost sharing or matching. The maximum award ceiling is $500,000. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for application submission is May 4, 2025. For more information and to apply, please visit the following link: [Tobacco Regulatory Science Grant](http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-017.html).
Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors. This initiative aims to advance the science of scale-up and sustainment by testing strategies to increase and sustain the delivery of tobacco use treatment (TUT) services for cancer survivors. Up to three research projects will be funded as part of this initiative. The funding will be in the form of a cooperative agreement, and there is no cost sharing or matching requirement. The estimated total program funding is $2,400,000, and it is expected that three awards will be granted. The funding opportunity is categorized under health and falls under the discretionary category. The eligible applicants are others, and the agency code is HHS-NIH11. The last updated date for this opportunity is July 19, 2024. The estimated synopsis post date is August 19, 2024, with an expected application due date in late Fall 2024. The estimated award date and project start date are both July 1, 2025.
Tuberculosis Elimination and Laboratory Cooperative Agreement
Active
Centers for Disease Control - NCHHSTP
The Centers for Disease Control - NCHHSTP is forecasting a cooperative agreement grant opportunity titled "TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT". This grant aims to continue complementing TB prevention and control and laboratory services at the state and local levels to reduce TB morbidity and mortality. The funding will be used to prevent the transmission of M. tuberculosis (TB) and prevent individuals from progressing from latent TB infection to TB disease. The grant will support various strategies and activities including diagnosis and treatment of persons with TB disease and latent TB infection, evaluation of immigrants and refugees with TB or latent TB infection, targeted testing and treatment of latent TB infection, program planning and evaluation, epidemiologic surveillance and response, human resource development and partnership activities, and public health laboratory strengthening. The expected outcomes of this grant include decreases in TB incidence, increases in patients completing treatment within 12 months, increases in TB cases with HIV and drug susceptibility testing results, increases in latent TB infection testing and treatment completion rates, improvement in accuracy and completeness of surveillance and laboratory data, improvement in turnaround times for laboratory testing, increases in programs implementing TB elimination plans, and increases in sharing of best practices within and between state and local programs. The estimated total program funding for this opportunity is $69,351,660, with an expected number of 61 awards to be granted. The application due date is September 6, 2024, and the estimated award date is December 2, 2024. For more information, you can contact Martha Boisseau at mboisseau@cdc.gov or 770-488-6261.
Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose
Active
Centers for Disease Control and Prevention - ERA
The Centers for Disease Control and Prevention - ERA is offering a cooperative agreement for the rigorous evaluation of primary and secondary overdose prevention activities among populations disproportionately affected by overdose. This funding opportunity aims to develop, implement, and evaluate prevention strategies for individuals or communities facing a higher risk of drug overdose or adverse outcomes related to drug use due to social determinants of health. The proposed research should focus on either primary prevention strategies to prevent adverse outcomes among those not yet engaged in drug use or secondary prevention strategies to reduce adverse outcomes among those already engaged in drug use by linking and retaining them in care. The evaluation should target at least two primary outcomes, such as nonfatal overdose, fatal overdose, substance use disorders involving federally illicit drugs or misuse of prescription medications, drug use, or initiation of drug use, particularly among youth. The estimated total program funding is $4,200,000, with an expected number of six awards. The deadline for electronically submitted applications is December 2, 2024, at 11:59 pm ET. For more information, contact Candis M. Hunter, PhD, MSPH, REHS at 770-488-1347 or ncipc_erpo@cdc.gov.
Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)". This grant aims to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research related to tobacco regulatory research. The grant will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing, with a focus on the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The grant does not require cost sharing or matching and falls under the category of health funding. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. The grant opportunity will close on March 12, 2025, and more information can be found at the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-024.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-024.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.